27.03
前日終値:
$28.00
開ける:
$28.04
24時間の取引高:
1.23M
Relative Volume:
0.56
時価総額:
$514.07M
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-18.51
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
-0.84%
1か月 パフォーマンス:
+10.42%
6か月 パフォーマンス:
+2,800%
1年 パフォーマンス:
+2,143%
Nektar Therapeutics Stock (NKTR) Company Profile
名前
Nektar Therapeutics
セクター
電話
(415) 482-5300
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NKTR
Nektar Therapeutics
|
27.03 | 521.68M | 90.12M | -276.06M | -193.47M | -1.46 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-24 | 繰り返されました | BTIG Research | Buy |
2025-06-24 | 繰り返されました | H.C. Wainwright | Buy |
2025-04-11 | アップグレード | Jefferies | Hold → Buy |
2025-03-14 | アップグレード | Oppenheimer | Perform → Outperform |
2025-01-08 | 開始されました | B. Riley Securities | Buy |
2024-12-10 | 開始されました | H.C. Wainwright | Buy |
2024-11-04 | 開始されました | Piper Sandler | Overweight |
2024-09-30 | 再開されました | BTIG Research | Buy |
2024-06-28 | 開始されました | Rodman & Renshaw | Buy |
2023-11-20 | 再開されました | JP Morgan | Underweight |
2023-11-09 | アップグレード | TD Cowen | Market Perform → Outperform |
2023-05-10 | アップグレード | Jefferies | Underperform → Hold |
2023-02-24 | ダウングレード | Jefferies | Hold → Underperform |
2022-08-08 | ダウングレード | JP Morgan | Neutral → Underweight |
2022-05-31 | 再開されました | Jefferies | Hold |
2022-04-18 | ダウングレード | Goldman | Neutral → Sell |
2022-03-15 | ダウングレード | Cowen | Outperform → Market Perform |
2022-03-15 | ダウングレード | Mizuho | Buy → Neutral |
2022-03-14 | ダウングレード | BTIG Research | Buy → Neutral |
2022-03-14 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-03-14 | ダウングレード | Stifel | Buy → Hold |
2022-03-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
2022-03-09 | アップグレード | Oppenheimer | Perform → Outperform |
2021-11-08 | アップグレード | The Benchmark Company | Hold → Buy |
2021-09-10 | 開始されました | BofA Securities | Neutral |
2021-06-28 | アップグレード | Stifel | Hold → Buy |
2021-05-18 | 再開されました | Goldman | Neutral |
2021-02-22 | ダウングレード | The Benchmark Company | Buy → Hold |
2021-01-06 | 開始されました | Stifel | Hold |
2020-09-14 | 開始されました | JP Morgan | Neutral |
2020-06-10 | ダウングレード | CFRA | Hold → Sell |
2020-05-12 | 繰り返されました | H.C. Wainwright | Neutral |
2020-04-22 | 開始されました | The Benchmark Company | Buy |
2020-03-30 | アップグレード | Goldman | Sell → Neutral |
2020-03-04 | 開始されました | Barclays | Overweight |
2020-02-03 | アップグレード | Mizuho | Neutral → Buy |
2019-10-24 | 開始されました | Oppenheimer | Perform |
2019-10-08 | ダウングレード | Goldman | Buy → Sell |
2019-08-09 | ダウングレード | JP Morgan | Overweight → Neutral |
2019-08-09 | ダウングレード | Jefferies | Buy → Hold |
2019-08-09 | ダウングレード | Mizuho | Buy → Neutral |
2019-03-15 | 開始されました | SVB Leerink | Mkt Perform |
2018-12-13 | 開始されました | Goldman | Buy |
2018-06-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2018-06-04 | 繰り返されました | H.C. Wainwright | Buy |
2018-04-20 | 開始されました | Seaport Global Securities | Buy |
2018-04-13 | 再開されました | Piper Jaffray | Overweight |
2018-04-06 | 繰り返されました | Mizuho | Buy |
2018-04-02 | 再開されました | H.C. Wainwright | Buy |
すべてを表示
Nektar Therapeutics (NKTR) 最新ニュース
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer - The Manila Times
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y - MSN
Can Nektar Therapeutics expand into new marketsWeekly Trade Report & AI Enhanced Trading Signals - thegnnews.com
Institutions Profited After Nektar Therapeutics' (NASDAQ:NKTR) Market Cap Rose US$80m Last Week but Retail Investors Profited the Most - 富途牛牛
Top 5 Articles of the Week: August 10-15 - Dermatology Times
Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout - MSN
Nektar Therapeutics Sees Relief Buying After Extended DropEarnings Overview Summary & Fast Exit Strategy with Risk Control - sundaytimes.kr
Nektar gets FDA fast track status for alopecia areata drug - MSN
Why Nektar Therapeutics Stock Popped 6% on Friday - MSN
Nektar Therapeutics shares fall 1.61% premarket as cancer research funding faces uncertainty. - AInvest
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment - MarketScreener
Nektar Therapeutics’ Earnings Call Highlights Growth Potential - TipRanks
Quant Tools Rank Nektar Therapeutics as High Risk High Reward2025 Stock Rankings & AI Powered Market Entry Strategies - metal.it
Institutional investors are Nektar Therapeutics' (NASDAQ:NKTR) biggest bettors and were rewarded after last week's US$59m market cap gain - simplywall.st
Nektar Therapeutics Rebounds From Oversold Zone — Now WhatLong Term Wealth Forecast - beatles.ru
Nektar Therapeutics (NASDAQ:NKTR) Q2 2025 Earnings Call Transcript - Insider Monkey
How Nektar's Rezpegaldesleukin Could Redefine Treatment for Autoimmune Disorders - Dermatology Times
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Nektar Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Nektar Therapeutics Q2 2025 Earnings: Revenue Exceeds Estimates, EPS Loss Wider Than Expected, Cash and Investments Down to $175.9 Million - AInvest
Nektar Therapeutics Q2 Earnings: Revenue Down, Net Loss Up, but Cash Position Strong and FDA Fast Track Designation for Rezpegaldesleukin - AInvest
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $98 to $120 - 富途牛牛
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Nektar Therapeutics 2025 Q2 Earnings Loss Narrows by 21.5% - AInvest
Nektar Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
Nektar Therapeutics (NKTR): A High-Risk, High-Reward Biotech Play in the Treg Space - AInvest
Nektar Therapeutics (NKTR) Stock Moves on Earnings and Fast Trac - GuruFocus
Jonathan Zalevsky, PhD, on Rezpegaldesleukin’s Biologic Approach to Alopecia Areata - Dermatology Times
Nektar Therapeutics: Operational Efficiency Gains Amid Revenue Decline—A Path to Profitability or a Temporary Reprieve? - AInvest
Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance - TipRanks
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛
William Blair Maintains Nektar Therapeutics(NKTR.US) With Hold Rating - 富途牛牛
Transcript : Nektar Therapeutics, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss By Investing.com - Investing.com Australia
Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss - Investing.com
Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments - TipRanks
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Highlights: Str - GuruFocus
Nektar (NKTR) Q2 Revenue Falls 52% - The Globe and Mail
Nektar Therapeutics (NKTR) 財務データ
収益
当期純利益
現金流量
EPS
Nektar Therapeutics (NKTR) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Wilson Mark Andrew | Chief Legal Officer |
Aug 19 '25 |
Sale |
26.59 |
676 |
17,975 |
20,312 |
ROBIN HOWARD W | President & CEO |
Aug 19 '25 |
Sale |
26.59 |
1,573 |
41,826 |
69,340 |
大文字化:
|
ボリューム (24 時間):